24 August 2022 – TMC Pharma Services (TMC) is a global clinical research organisation that specialises in innovative treatments for orphan, rare and oncology diseases. TMC has successfully supported over 200 Orphan Drug Designations in the past 10 years; in the USA, EU, Japan and Australia. The business provides a full range of expert pharma and biotech support services, from pre-clinical to post-marketing, for human medicines and devices.  TMC’s senior team, based in the UK, is supported by a worldwide network of over 900 contracted Associates, who are hand-picked to match the exact needs of each individual project. TMC’s network of Associates includes some of the very best subject-matter experts in medicinal product development in the world.

Established in 2001, TMC operates globally across four offices and hubs in the UK, Ireland, Japan and the US. The business has more than doubled its revenues over the past five years to £11.8m in 2021.

LDC is backing the existing management team, led by Co-Founder and CEO Julie Matthews. Its minority investment will help TMC to further expand into the US and Asia markets. The business also plans to double the number of full-time employees it has over the next five years and open new offices in key international markets.

The transaction was led by Dewi Hughes, Partner and Head of the South West & Wales at LDC, and Investment Director Stefan Gunn, both of whom will join the TMC board.  As part of the transaction Pharma expert and entrepreneur Thomas Engelen is joining the board as Non-Executive Chair.

Julie Matthews, CEO at TMC Pharma Services, said: “Our unique business model has worked outstandingly well over the last 20 years, including navigating a challenging COVID period successfully. We have been delighted to help many clients to bring valuable treatments to patients, especially those with rare and orphan diseases with few therapy options. Now, with LDC’s support we are entering an exciting next phase, where we will further strengthen our team, and expand our global reach, for the benefit of patients with unmet medical needs, our clients and for our staff and Associates.”

“LDC’s relationship-focused approach, coupled with their sector knowledge and experience of supporting international growth strategies made them the perfect choice of partner to support TMC on the journey ahead.” 

Julie Matthews, CEO, TMC Pharma Services

Published On: 21 December 2023By Categories: News